Plus Therapeutics Inc (NASDAQ: PSTV) on Monday, plunged -5.57% from the previous trading day, before settling in for the closing price of $0.58. Within the past 52 weeks, PSTV’s price has moved between $0.16 and $2.31.
During the last 5-year period, the sales growth of Healthcare Sector giant was 46.51%. The company achieved an average annual earnings per share of 87.69%. With a float of $136.95 million, this company’s outstanding shares have now reached $137.43 million.
Plus Therapeutics Inc (PSTV) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Plus Therapeutics Inc is 0.35%, while institutional ownership is 4.89%. The most recent insider transaction that took place on Nov 04 ’25, was worth 10,200. In this transaction Chief Financial Officer of this company bought 20,000 shares at a rate of $0.51, taking the stock ownership to the 68,138 shares. Before that another transaction happened on Aug 22 ’25, when Company’s Director bought 110,000 for $0.49, making the entire transaction worth $53,779. This insider now owns 139,327 shares in total.
Plus Therapeutics Inc (PSTV) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.49 earnings per share (EPS) for the period topping the consensus outlook (set at -0.5) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.04% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Plus Therapeutics Inc (PSTV) is currently performing well based on its current performance indicators. A quick ratio of 1.27 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Looking closely at Plus Therapeutics Inc (NASDAQ: PSTV), its last 5-days average volume was 2.58 million, which is a drop from its year-to-date volume of 17.85 million. As of the previous 9 days, the stock’s Stochastic %D was 19.42%.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 29.46%, which indicates a significant increase from 6.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0520 in the past 14 days, which was lower than the 0.0614 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5780, while its 200-day Moving Average is $0.5699. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.5671. Second resistance stands at $0.5866. The third major resistance level sits at $0.5993. If the price goes on to break the first support level at $0.5349, it is likely to go to the next support level at $0.5222. Should the price break the second support level, the third support level stands at $0.5027.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
Market capitalization of the company is 75.26 million based on 137,429K outstanding shares. Right now, sales total 5,820 K and income totals -12,980 K. The company made 1,400 K in profit during its latest quarter, and -4,420 K in sales during its previous quarter.
